Vivoryon Therapeutics N.V. Signs Financing Agreement
for up to EUR 15 Million
Halle (Saale) / Munich, Germany, April 24, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (“Vivoryon” or the “Company”), a clinical-stage pharmaceutical company focused on creating small molecule drugs that alter the behavior of disease-causing proteins, has announced a Standby Equity Purchase Agreement (“SEPA”) with Yorkville Advisors Global, LP (“Yorkville”), a New Jersey-based institutional investor, for up to EUR 15 million.
The agreement stipulates that Yorkville will purchase up to EUR 15 million worth of Vivoryon’s ordinary shares over 36 months from the agreement’s commencement. Vivoryon retains the option, but not the obligation, to sell these shares to Yorkville in separate tranches, without offering pre-emptive rights to existing shareholders.
Anne Doering, CFA, CFO of Vivoryon, stated, “This agreement gives Vivoryon the financial resources to move forward with preparations for our planned Phase 2b study in diabetic kidney disease. We believe this facility provides solid capital support, while also allowing us to actively explore further funding opportunities to fully execute the Phase 2b study. Yorkville has a strong history of providing capital to biotechnology companies, and we are pleased to partner with them to support our strategy of developing varoglutamstat as a uniquely positioned treatment to address the unmet needs of kidney disease patients.”
Each tranche can include shares equal to 100% of the average daily trading volume of ordinary shares in the five trading days leading up to the tranche request date. Vivoryon and Yorkville can mutually agree to increase the number of shares per tranche, with a maximum of 389,359 shares (subject to a potentially higher maximum agreed upon by both parties). The ordinary shares will be issued at a 5% discount from the current market price. Yorkville intends to sell the shares from each tranche request on the market after receiving the request. The agreement also includes the issuance of 167,028 shares to Yorkville as a commitment fee. To facilitate the transaction, Erich Platzer, MD, PhD, through PlatzerInvest AG, and Frank Weber, MD, both board members of the Company, have entered into a share lending agreement with Yorkville, where Dr. Platzer and Dr. Weber will lend 389,359 ordinary shares to Yorkville without compensation.
Vivoryon plans to use the funds generated through the SEPA to support its ongoing business operations, continue preparing for the Phase 2b study of its main drug candidate, varoglutamstat, for diabetic kidney disease, and further preclinical studies of its new development candidate, VY2149.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotech company focused on creating innovative small molecule-based drugs. Driven by its dedication to pioneering science and innovation, the Company aims to improve the lives of patients suffering from severe diseases. The Company uses its deep knowledge of post-translational modifications to create medicines that change the activity and stability of proteins altered in disease. The Company has built a pipeline of oral small molecule inhibitors for various indications, including Alzheimer’s disease, inflammatory and fibrotic disorders (including kidney disorders), and cancer.
Vivoryon Forward Looking Statements
This press release contains forward-looking statements regarding the business strategy, management plans, and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), as well as estimates, projections, market forecasts, and statements about the potential availability of the Company’s products. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should,” and “will,” and similar expressions are used to identify these forward-looking statements. These statements are based on management’s current expectations and assumptions about future events, trends, the economy, and other conditions and are not guarantees of future performance. Forward-looking statements involve known and unknown risks and uncertainties that could significantly affect the outcome and financial impact of the plans and events described. The Company’s actual results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies, or events may differ materially from those expressed or implied in these forward-looking statements. Therefore, undue reliance should not be placed on these statements. This press release does not include risk factors. Risk factors that could affect the Company’s future financial results are discussed in the Company’s published annual financial statements. This press release, including all forward-looking statements, is relevant only as of the date of its release. The Company undertakes no obligation to update any information or forward-looking statements contained herein, except as required by law.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email:
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email:
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email:
Attachment
“`